Abstract
Deguelin is the major active ingredient and principal component in cube resin, derived from Lonchocarpus utilis and used as a botanical insecticide and pesticide in Africa, South America and China. A growing body of evidence indicates that deguelin has a very strong anti-tumor effect on malignant cells without compromising normal cells. As a complex natural extract, deguelin interacts with various molecular targets to exert its anti-tumor properties at nanomolar levels. This current review delineates the molecular mechanism of the anti-tumor activities of deguelin in malignancies. Our research shows that the multiple and extensive biological effects of deguelin are mediated via interactions with target points involved in cell proliferation pathways (cyclin D1, pRb), cell apoptosis pathways (NF-κB, IκBα, Bcl-2, Bcl-xl, survivin), the nucleophosmin and nucleoporins pathways (Nup88, Nup98, Nup214), as well as through the regulation of steroid receptor co-activator SRC-3 and DNA Topoisomerase. In addition, deguelin holds a promising efficacy for reversing drug resistance.
Keywords: Anti-tumor, Bcl-xl, Bcl-2, Cyclin D1, Deguelin, IκBα, NF-κB, NPM, NUPs, pRb, SRC-3, Survivin
Current Pharmaceutical Analysis
Title: Molecular Mechanism of Deguelin in Anti-tumor Effect
Volume: 8 Issue: 1
Author(s): Lu Wen and Yan Chen
Affiliation:
Keywords: Anti-tumor, Bcl-xl, Bcl-2, Cyclin D1, Deguelin, IκBα, NF-κB, NPM, NUPs, pRb, SRC-3, Survivin
Abstract: Deguelin is the major active ingredient and principal component in cube resin, derived from Lonchocarpus utilis and used as a botanical insecticide and pesticide in Africa, South America and China. A growing body of evidence indicates that deguelin has a very strong anti-tumor effect on malignant cells without compromising normal cells. As a complex natural extract, deguelin interacts with various molecular targets to exert its anti-tumor properties at nanomolar levels. This current review delineates the molecular mechanism of the anti-tumor activities of deguelin in malignancies. Our research shows that the multiple and extensive biological effects of deguelin are mediated via interactions with target points involved in cell proliferation pathways (cyclin D1, pRb), cell apoptosis pathways (NF-κB, IκBα, Bcl-2, Bcl-xl, survivin), the nucleophosmin and nucleoporins pathways (Nup88, Nup98, Nup214), as well as through the regulation of steroid receptor co-activator SRC-3 and DNA Topoisomerase. In addition, deguelin holds a promising efficacy for reversing drug resistance.
Export Options
About this article
Cite this article as:
Wen Lu and Chen Yan, Molecular Mechanism of Deguelin in Anti-tumor Effect, Current Pharmaceutical Analysis 2012; 8 (1) . https://dx.doi.org/10.2174/157341212798995467
DOI https://dx.doi.org/10.2174/157341212798995467 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
COVID-19 Related Coagulopathy: What is Known Up to Now
Current Medicinal Chemistry Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment
Current Drug Targets Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Hedgehog Signaling and Urological Cancers
Current Drug Targets Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemical and Medicinal Versatility of Dithiocarbamates: An Overview
Mini-Reviews in Medicinal Chemistry MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Current Drug Targets Opioid Free Anaesthesia and Cancer
Current Pharmaceutical Design Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Cancer Immunotherapy Using Gene-Modified Dendritic Cells
Current Gene Therapy Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety The Nuclear Orphan Receptor NR4A1 and NR4A3 as Tumor Suppressors in Hematologic Neoplasms
Current Drug Targets